Please assess the completion status of the following clinical trial:

Trial Title: Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the criteria for a United Network for Organ Sharing (UNOS) Status 1B heart transplant candidate, or, if outside the US, have comparable status~* must also be a primary transplant candidate waiting to receive a single cardiac allograft~* must be receiving continuous intravenous infusion of dobutamine or milrinone through a double-lumen central catheter or a double-lumen percutaneously inserted central catheter for at least 3 consecutive days before randomization~* must be willing and able to participate in the study assessments and follow up procedures~* male and female subjects of childbearing potential agree to use two highly effective methods of birth control for the duration of the study.~Exclusion Criteria:~* Not have systolic blood pressure (SBP) consistently \< 80 mm Hg, or have clinically significant orthostatic hypotension~* not weigh \> 130 kg~* not have a ventricular assist device (VAD), or anticipate the need for a VAD, during the 28-day study drug treatment period~* not have received placement of an internal cardiac defibrillator (ICD) or external cardiac defibrillator (ECD) within 72 hours before randomization~* not require chronic hemodialysis or peritoneal dialysis to treat renal failure, or had acute dialysis or ultrafiltration within 7 days before randomization~* not have received antibiotic treatment within 7 days before randomization-antibiotics are permissible for any prophylactic use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Natrecor (nesiritide)+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
- 002 (Type: PLACEBO_COMPARATOR): Placebo+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).